An update on primary hyperoxaluria
- PMID: 22688746
- DOI: 10.1038/nrneph.2012.113
An update on primary hyperoxaluria
Abstract
The autosomal recessive inherited primary hyperoxalurias types I, II and III are caused by defects in glyoxylate metabolism that lead to the endogenous overproduction of oxalate. Type III primary hyperoxaluria was first described in 2010 and further types are likely to exist. In all forms, urinary excretion of oxalate is strongly elevated (>1 mmol/1.73 m(2) body surface area per day; normal <0.5 mmol/1.73 m(2) body surface area per day), which results in recurrent urolithiasis and/or progressive nephrocalcinosis. All entities can induce kidney damage, which is followed by reduced oxalate elimination and consequent systemic deposition of calcium oxalate crystals. Systemic oxalosis should be prevented, but diagnosis is all too often missed or delayed until end-stage renal disease (ESRD) occurs; this outcome occurs in >30% of patients with primary hyperoxaluria type I. The fact that such a large proportion of patients have such poor outcomes is particularly unfortunate as ESRD can be delayed or even prevented by early intervention. Treatment options for primary hyperoxaluria include alkaline citrate, orthophosphate, or magnesium. In addition, pyridoxine treatment can be used to normalize or reduce oxalate excretion in about 30% of patients with primary hyperoxaluria type I. Time on dialysis should be short to avoid overt systemic oxalosis. Transplantation methods depend on the type of primary hyperoxaluria and on the particular patient, but combined liver and kidney transplantation is the method of choice in patients with primary hyperoxaluria type I and isolated kidney transplantation is the preferred method in those with primary hyperoxaluria type II. To the best of our knowledge, progression to ESRD has not yet been reported in any patient with primary hyperoxaluria type III.
Similar articles
-
The primary hyperoxalurias.Kidney Int. 2009 Jun;75(12):1264-1271. doi: 10.1038/ki.2009.32. Epub 2009 Feb 18. Kidney Int. 2009. PMID: 19225556 Free PMC article. Review.
-
[Primary hyperoxaluria: A review].Nephrol Ther. 2016 Nov;12(6):431-436. doi: 10.1016/j.nephro.2016.03.005. Epub 2016 Jun 29. Nephrol Ther. 2016. PMID: 27372182 Review. French.
-
Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment.Nephrol Dial Transplant. 2012 May;27(5):1729-36. doi: 10.1093/ndt/gfs078. Nephrol Dial Transplant. 2012. PMID: 22547750
-
Recent advances in the identification and management of inherited hyperoxalurias.Urolithiasis. 2019 Feb;47(1):79-89. doi: 10.1007/s00240-018-1093-3. Epub 2018 Dec 10. Urolithiasis. 2019. PMID: 30535828 Review.
-
[Primary hyperoxaluria].Nephrol Ther. 2011 Jul;7(4):249-59. doi: 10.1016/j.nephro.2011.03.004. Epub 2011 Jun 2. Nephrol Ther. 2011. PMID: 21636340 French.
Cited by
-
Primary hyperoxaluria type 3: from infancy to adulthood in a genetically unique cohort.Pediatr Nephrol. 2024 Oct 30. doi: 10.1007/s00467-024-06536-w. Online ahead of print. Pediatr Nephrol. 2024. PMID: 39476025
-
Oxygen control in bioreactor drives high yield production of functional hiPSC-like hepatocytes for advanced liver disease modelling.Sci Rep. 2024 Oct 19;14(1):24599. doi: 10.1038/s41598-024-75582-z. Sci Rep. 2024. PMID: 39427033 Free PMC article.
-
Multiomics Assessment of the Gut Microbiome in Rare Hyperoxaluric Conditions.Kidney Int Rep. 2024 Mar 11;9(6):1836-1848. doi: 10.1016/j.ekir.2024.03.004. eCollection 2024 Jun. Kidney Int Rep. 2024. PMID: 38899198 Free PMC article.
-
Lumasiran treatment in pediatric patients with PH1: real-world data within a compassionate use program in Italy.Clin Kidney J. 2024 Mar 28;17(5):sfae090. doi: 10.1093/ckj/sfae090. eCollection 2024 May. Clin Kidney J. 2024. PMID: 38742209 Free PMC article.
-
Simultaneous Liver Kidney Transplantation in a Primary Type 2 Hyperoxaluria With Corrected TOF and Severe Cardiomyopathy: A Case Report.J Clin Exp Hepatol. 2024 Sep-Oct;14(5):101425. doi: 10.1016/j.jceh.2024.101425. Epub 2024 Apr 16. J Clin Exp Hepatol. 2024. PMID: 38721383
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous